ALDR News and Press, Alder BioPharmaceuticals Inc. From 04/02/19

BOTHELL, Wash., April 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview...

BOTHELL, Wash, March 05, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder’s president and chief executive officer...

Alder BioPharmaceuticals (NASDAQ: ALDR ) closes its previously announced public offering of 13M shares of common stock, priced at $11.50/share. More news on: Alder Biopharmaceuticals Inc., Healthcare stocks news, Read more ...

BOTHELL, Wash., March 04, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today the closing of its previously announced underwritten public offerin...

Alder BioPharmaceuticals (NASDAQ: ALDR ) prices its public offering of ~11.3M shares of common stock at $11.50 per share. Underwriters over-allotment is an additional ~1.7M shares. Closing date is March 4. More news on: Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the...

BOTHELL, Wash., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today the pricing of an underwritten public offering of 11,304,348 shares ...

BOTHELL, Wash., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today that it intends to offer and sell, subject to market and other condi...

Alder Biopharmaceuticals Inc. (ALDR) Q4 2018 Earnings Conference Call February 25, 2019 5:00 PM ET Company Participants Michael Schaffzin - Stern, Investor Relations Bob Azelby - Chief Executive Officer Carlos Campoy - Chief Executive Officer John Latham - Chief Scientific Offi...

Alder Bio (NASDAQ: ALDR ): Q4 GAAP EPS of -$1.19 misses by $0.24. More news on: Alder Biopharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Completes eptinezumab’s Biologics License Application (BLA) submission - - Remains on track for eptinezumab’s commercial launch in Q1-2020 - - Strengthens leadership team with the appointments of Carlos Campoy as Chief Financial Officer and Dr. Paul Streck as C...